Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.…
Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer
Adagene (NASDAQ: ADAG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 128 employees.
The shares were at 1.760 USD on 20 November 2026, down 0.6% over 52 weeks. Its 52-week range is 1.267 USD to 4.850 USD: the price is 63.7% below the high and 38.9% above the low.
Its market capitalisation is 118.17M USD.
Adagene reports return on equity of -49.8% and an operating margin of -240.4%.
It holds more cash than debt, a net cash position of 121.82M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health.